Cyclo-oxygenase inhibitors and Alzheimer's: Are we well ADAPTed? [1]

Lancet Neurology

Volumn 1, Issue 7, 2002, Pages 403-404

  Pasinetti, Giulio Maria ^a   Pompl, Patrick Nicholas ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; EPIDEMIOLOGICAL DATA; EXPERIMENT; HIGH RISK PATIENT; HUMAN; INHIBITION KINETICS; LETTER; METHODOLOGY; NERVE DEGENERATION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; AGED; BRAIN; EDITORIAL; ENZYMOLOGY; ETHICS; LEGAL ASPECT; METABOLISM; PATHOPHYSIOLOGY; PATIENT SELECTION; PROFESSIONAL STANDARD; STANDARD;

AGED; ALZHEIMER DISEASE; BRAIN; CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; CYCLOOXYGENASE INHIBITORS; HUMANS; PATIENT SELECTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0041628645     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00214-4     Document Type: Letter

References (13)

1. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclo-oxygenase activity. Nature. 414:2001;212-216.
2. Breteler M, in 't Veld B, Hofman A, Stricker B. Abeta42 peptide lowering NSAIDs and Alzheimer's disease. http://www.congrex.com/scripts/cainii/cainabstract.asp?Conf_Id= '02070203'&Serial_Number=2753. (Accessed Oct 2, 2002).
3. in 't Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 345:2001;1515-1521.
4. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
5. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:1999;197-201.
6. Zandi P.P., Breitner J.C. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging. 22:2001;811-817.
7. Pasinetti G.M. Cyclo-oxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. Arch Gerontol Geriatr. 33:2001;13-28.
8. Raz A. Is inhibition of cyclo-oxygenase required for the antitumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs): in vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol. 63:2002;343-347.
9. Clements P.J., Paulus H.E. Nonsteroidal anti-inflammatory drugs (NSAIDs). Kelley W.N., Harris E.D. Jr, Ruddy S., Sledge C.B. Textbook of rheumatology. 1993;700-730 WB Saunders Company, Philadelphia.
10. Ho L., Purohit D., Haroutunian V., et al. Neuronal cyclooxygenase-2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 58:2001;487-492.
11. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 20:2000;5709-5714.
12. Xiang Z., Ho L., Yemul S., et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expression. 10:2002;271-278.
13. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C.S. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 59:2002;880-886.